Safety and Efficacy Study of Novel Gene Therapy ZM-02 for Retinitis Pigmentosa Patients

This study is testing a new gene therapy called ZM-02 for people with retinitis pigmentosa (RP) — a genetic eye disease where the light-sensing cells in the retina slowly break down over time, leading to progressive vision loss and potentially blindness. **You may be eligible if...** - You have been clinically diagnosed with retinitis pigmentosa - Your vision in the study eye is very poor (no better than being able to count fingers) but not total darkness — you must have had better vision in the past - An OCT eye scan shows specific retinal findings: the outer photoreceptor layer (ellipsoid zone) has disappeared, but inner retinal layers are still present - Your eye prescription is between -6.00 and +6.00 diopters - You do not have HIV or other active infectious diseases **You may NOT be eligible if...** - You have no remaining functional inner retinal layers - You have total blindness with no prior visual experience - You have HIV or another serious active infection Talk to your doctor to see if this trial is right for you.